• GlucoTrack entered a securities purchase agreement on Aug. 4, 2026 for a private placement with a PIPE investor.
• Closing included pre-funded warrants for common stock, plus common stock purchase warrants for common stock.
• Warrant terms amended on Sept. 14, 2026 to bar exercise until stockholder approval under Nasdaq Listing Rule 5635(d).
• Share issuance under the common stock purchase warrants now contingent on that stockholder vote.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-042582), on September 14, 2026, and is solely responsible for the information contained therein.